期刊文献+

HPLC法测定维格列汀片中主药和有关物质的含量 被引量:1

Content Determination of Main Components and Related Substances in Vildagliptin Tablets by HPLC
原文传递
导出
摘要 目的:建立测定维格列汀片中主药和有关物质含量的方法。方法:采用高效液相色谱法。色谱柱为Phenomenex LunaC18,流动相为0.01mo·lL-1磷酸氢二钾溶液-乙腈(75∶25),流速为1.0mL·min-1,检测波长为210nm,进样量为20μL。结果:维格列汀检测浓度的线性范围为25.0~225.0μg·mL-1(r=0.9999);平均回收率为99.60%(RSD=0.77%)。3批样品中主药标示含量分别为99.46%、98.94%、99.61%,有关物质含量分别为0.37%、0.22%、0.56%。结论:本方法操作简便、快捷,结果准确、可靠,可用于维格列汀片的质量控制。 OBJECTIVE:To establish a method for the determination of the vildagliptin and the related substances in Vildagliptin tablets.METHODS:HPLC method was adopted.The determination was performed on Phenomenex Luna C18 with mobile phase consisted of 0.01 mol·L-1 dipotassium hydrogen phosphate solution-acetonitril(75 ∶ 25) at flow rate of 1.0 mL·min-1.The detection wavelength was set 210 nm and the sample size was 20 μL.RESULTS:The linear range of vildagliptin was 25.0~225.0 μg·mL-1(r=0.999 9) with an average recovery of 99.60%(RSD=0.77%) .The labeling amounts of main components of 3 batches of samples were 99.46%,98.94% and 99.61%.The contents of relevant substances were 0.37%,0.22%,0.56%.CONCLUSIONS:The method is simple,rapid,accurate and reliable,and it is applicable for the quality control of Vildagliptin tablets.
出处 《中国药房》 CAS CSCD 北大核心 2011年第21期1992-1993,共2页 China Pharmacy
关键词 高效液相色谱法 维格列汀 片剂 有关物质 含量测定 HPLC Vildagliptin Tablets Related substance Content determination
  • 相关文献

参考文献1

二级参考文献15

  • 1夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量:26
  • 2PRATLEY RE, SALSALI A, MATFIN G. Inhibition of dipeptidyl peptidase-4 with vildagliptin : a potential new treatment for type 2 diabetes[ J]. Br J Diabetes Vasc Dis,2006,6(4) : 150 - 156.
  • 3VILLHAUER EB, BRINKMAN JA, NADERI GB, et al. 1-[ [ ( 3- hydroxy-1 - adamantyl ) amino ] acetyl ] -2-cyano-( S ) - pyrrolidine : a potent, selective, and orally bioavailable dipeptidyl peptidase Ⅳ inhibitor with antihyperglycemic properties[ J ]. J Med Chem, 2003,46 ( 13 ) :2774 - 2789.
  • 4MARGUET D, BAGGIO L,KOBAYASHI,et al. Enhanced insulin secretion and inproved glucose tolerance in mice lacking CD26 [ J ]. Proc Natl Acad Sci USA ,2000,97 ( 12 ) :6874 - 6879.
  • 5NAGAKUBA T, YASUDA N,YAMAZAKI K,et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptldyl peptidase Ⅳ- deficient Fischer rats [ J ]. Biochem Biophys Res Commun,2001,284(2 ) :501 - 506.
  • 6HE Y,BALCH A, CAMPESTRINI J, et al. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes [ J ]. Clin Pharmacol Ther,2005,77 ( 2 ) :56.
  • 7HE YL,SABO R,CAMPESTRINI J ,et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase Ⅳ ( DDP-4 ) inhibitor vildagliptin [ J ]. Eur J. Clin Pharm,2007, 63(7) :677 -686.
  • 8PRATLEY RE, JAUFFRET-KAMEL S, GALBREATH E,et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes [ J ]. Horm Metab Res ,2006,38 ( 6 ) :423 - 428.
  • 9RISTIC S, BYIERS S, FOLEY J,et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin ( LAF237 ) dose response [ J ]. Diabetes Obes Metab,2005,7 ( 6 ) : 692 - 698.
  • 10BOSI E,CAMISASCA RP,COLLOBER C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [ J ]. Diabetes Care, 2007,30(4) :890 - 895.

共引文献28

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部